- Market Capitalization, $K 128,302,056
- Shares Outstanding, K 2,623,764
- Annual Sales, $ 22,090 M
- Annual Income, $ 2,155 M
- 60-Month Beta 0.46
- Price/Sales 5.32
- Price/Cash Flow 15.34
- Price/Book 9.46
|Period||Period Low||Period High||Performance|
| || |
-1.54 (-3.05%)since 12/27/19
| || |
+1.23 (+2.58%)since 10/25/19
| || |
+13.15 (+36.78%)since 01/25/19
High-level results from the Phase III THALES trial showed AstraZeneca's BRILINTA (ticagrelor) 90 mg used twice daily and taken with aspirin for 30 days, reached a statistically significant and clinically...
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan (NYSE: AGN), a leading global pharmaceutical company, today announced that Allergan has entered into definitive agreements...
Roche's (RHHBY) study on Tecentriq in muscle-invasive urothelial cancer fails to meet goals.
J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and the...
While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q4 sales, generic competition for Lyrica is likely to have hurt the same.
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
A recent report provides crucial insights along with application based and forecast information in the Global Gastro Esophageal Reflux Disease Drug and Devices Market. The report provides a comprehensive...
Top Stock Research Reports for Roche, Royal Dutch Shell & Citigroup
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food...
|Advisorshares Doubleline Value Equity ETF|
|Schwab Fundamental Intl Large Company|
|Goldman Sachs Access Investment Grade Corp Bond|
|IQ 500 International ETF|
|Advisorshares Dorsey Wright ADR|